Pharsight

Vagifem patents expiration

VAGIFEM's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5860946 NOVO NORDISK INC Instrument for inserting a suppository
Jul, 2017

(6 years ago)

US7018992 NOVO NORDISK INC Hormone composition
Sep, 2022

(1 year, 8 months ago)

Vagifem is owned by Novo Nordisk Inc.

Vagifem contains Estradiol.

Vagifem has a total of 2 drug patents out of which 2 drug patents have expired.

Expired drug patents of Vagifem are:

  • US5860946
  • US7018992

Vagifem was authorised for market use on 25 November, 2009.

Vagifem is available in tablet;vaginal dosage forms.

Vagifem can be used as treatment of atrophic vaginitis due to menopause.

The generics of Vagifem are possible to be released after 17 September, 2022.

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-122) Nov 25, 2012

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 25 November, 2009

Treatment: Treatment of atrophic vaginitis due to menopause

Dosage: TABLET;VAGINAL

How can I launch a generic of VAGIFEM before it's drug patent expiration?
More Information on Dosage

VAGIFEM family patents

Family Patents